Viracept (Nelfinavir Mesylate) - Summary

VIRACEPT SUMMARY

VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease. VIRACEPT Tablets are available for oral administration as a light blue, capsule-shaped tablet with a clear film coating in 250 mg strength (as nelfinavir free base) and as a white oval tablet with a clear film coating in 625 mg strength (as nelfinavir free base).

VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV infection.

See all Viracept indications & dosage >>

VIRACEPT NEWS HIGHLIGHTS

Published Studies Related to Viracept (Nelfinavir)

Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. [2008.01]

Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. [2007.08.15]

A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. [2006.03]

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. [2005.12.01]

Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. [2005.10.15]

more >>

Clinical Trials Related to Viracept (Nelfinavir)

Safety Of VIRACEPT; 625 mg Administered To HIV-Infected Women During Pregnancy [Completed]

A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea [Terminated]

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients [Suspended]

Viracept Expanded Access Program [Completed]

The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine [Completed]

more >>